Ferring Pharmaceuticals and SK pharmteco have agreed to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.   Following technology transfer, SK pharmteco, a contract development manufacturing organization (CDMO), will be qualified as another source for manufacturing, testing, and release of the medicine, subject to regulatory approval by the U.S...